Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Diagnostic Value of [68Ga]Ga-Pentixafor Versus [18F]Fdg Pet/Cts in Non-Small Cell Lung Cancer: A Head-To-Head Comparative Study Publisher Pubmed



Mirshahvalad SA1 ; Manafifarid R1 ; Fallahi B1 ; Seifi S2 ; Geramifar P1 ; Emamiardekani A1 ; Eftekhari M1 ; Beiki D1
Authors

Source: Nuclear Medicine Communications Published:2023


Abstract

Objective In this study, we aimed to compare the diagnostic value of [68Ga]Ga-Pentixafor and [18F]FDG PET/CT in the evaluation of non-small cell lung cancer (NSCLC) patients. Methods Patients with pathology-proven NSCLC were prospectively included. Patients underwent [18F]FDG and [68Ga]Ga-Pentixafor PET/CT within 1 week. All suspicious lesions were interpreted as benign or malignant, and the corresponding PET/CT semi-quantitative parameters were recorded. A two-sided P-value <0.05 was considered significant. Results Twelve consecutive NSCLC patients (mean age: 60 ± 7) were included. All patients underwent both [18F]FDG and [68Ga]Ga-Pentixafor PET/CT scans with a median interval of 2 days. Overall, 73 abnormal lesions were detected, from which 58 (79%) were concordant between [18F]FDG and [68Ga]Ga-Pentixafor PET/CT. All primary tumors were clearly detectable in both scans visually. Also, [68Ga]Ga-Pentixafor PET/CT demonstrated rather comparable results with [18F]FDG PET/CT scan in detecting metastatic lesions. However, malignant lesions demonstrated significantly higher SUVmax and SUVmean in [18F]FDG PET/CT (P-values <0.05). Regarding the advantages, [68Ga]Ga-Pentixafor depicted two brain metastases that were missed by [18F]FDG PET/CT. Also, a highly suspicious lesion for recurrence on [18F]FDG PET/CT scan was correctly classified as benign by subsequent [68Ga]Ga-Pentixafor PET/CT. Conclusion [68Ga]Ga-Pentixafor PET/CT was concordant with [18F]FDG PET/CT in detecting primary NSCLC tumors and could visualize the majority of metastatic lesions. Moreover, this modality was found to be potentially helpful in excluding tumoural lesions when the [18F]FDG PET/CT was equivocal, as well as in detecting brain metastasis where [18F]FDG PET/CT suffers from poor sensitivity. However, the count statistics were significantly lower. © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Related Docs
View other Related Docs
1. Diagnostic Value of [68Ga]Ga-Pentixafor Pet/Ct in Malignant Melanoma: A Pilot Study, Nuclear Medicine Communications (2024)
2. The Role of 1H-Mrs and [18F]Fdg Pet/Ct in Differentiating Primary Squamous Cell Carcinoma and Metastatic Hodgkin's Lymphoma in Lung: An Experimental Pilot Study, Iranian Journal of Nuclear Medicine (2024)
3. Enhancing Radiomics Robustness Using Bayesian Penalized Likelihood Pet Reconstruction: Application to Phantom and Non-Small Cell Lung Cancer Patient Studies, BMC Medical Imaging (2025)
Experts (# of related papers)
View all Related Experts
Reyhaneh Manafi-Farid (4)
Naghmeh Bahrami (3)
Other Related Docs
4. Additional Value of 2-[18 F]Fdg Pet/Ct Comparing to Mri in Treatment Approach of Anal Cancer Patients, Journal of Clinical Medicine (2020)
5. Analysis of the Relationship Between Egfr Mutations and Pd-L1, Alk, and Ros1 Alterations in Patients With Non- Small-Cell Lung Cancer: The Most Extensive Study Conducted in Iran; [Analysis of the Relationship Between Egfr Mutations and Pd-L1, Alk, and Ros1 Alterations in Patients With Non- Small-Cell Lung Cancer: The Most Extensive Study Conducted in Iran], Turk patoloji dergisi (2025)
6. The Impact of Preprocessing on the Pet-Ct Radiomics Features in Non-Small Cell Lung Cancer, Frontiers in Biomedical Technologies (2021)
7. [68Ga]Ga-Psma-11 Pet/Ct and [18F]Fluorocholine Pet/Ct in Assessment and Clinical Decision Making of Recurrent Prostate Cancer: A Prospective Crossover Trial, Molecular Imaging and Biology (2025)
8. New Insights Into Designing Hybrid Nanoparticles for Lung Cancer: Diagnosis and Treatment, Journal of Controlled Release (2019)
9. Predictive Molecular Blood Biomarkers in Non-Small Cell Lung Cancer, Journal of Cellular and Molecular Anesthesia (2022)
10. Pet in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin, PET Clinics (2018)
11. Expression of Mir-155 and Cea and Vegf Proteins As Diagnostic Markers in Early Stages of Non-Small Cell Lung Cancer in Peripheral Blood, Tanaffos (2024)
12. Enhanced Staging of Extrahepatic Hepatocellular Carcinoma Metastasis Through Dual-Tracer Pet/Computed Tomography: A Systematic Review and Meta-Analysis, Nuclear Medicine Communications (2024)
13. 2-[18F]Fdg Pet/Ct Radiomics in Lung Cancer: An Overview of the Technical Aspect and Its Emerging Role in Management of the Disease, Methods (2021)
14. Delta Changes in [18F]Fdg Pet/Ct Parameters Can Prognosticate Clinical Outcomes in Recurrent Nsclc Patients Who Have Undergone Reirradiation–Chemoimmunotherapy, Biomedicines (2025)
15. The Effect of Harmonization on the Variability of Pet Radiomic Features Extracted Using Various Segmentation Methods, Annals of Nuclear Medicine (2024)
16. Comparing the Sensitivity and Specificity of Lung Ct-Scan With Rt-Pcr for Diagnosis of Covid-19, Current Medical Imaging (2023)
17. Comparison of Diagnostic Performance of [68Ga]-Ga-Fapi-46 and [18F]-Fdg Pet/Ct Imaging for the Detection of Lesions and Disease Staging in Patients With Breast Cancer, Asia Oceania Journal of Nuclear Medicine and Biology (2025)
18. The Clinicopathologic and Prognostic Value of Cd44 Expression in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis, Molecular and Cellular Probes (2025)
19. Qualitative and Quantitative Differentiation Efficiency of Dual-Tracer Pet/Ct With 18F-Fluorodeoxyglucose and 11C-Acetate for Primary Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis, Abdominal Radiology (2025)
20. A Pilot Study of Ck20 Mrna, Vegf Mrna, Vegf Protein in the Peripheral Blood of Patients With Non-Small Cell Lung Cancer, Minerva Pneumologica (2017)